Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Part B Demo To Be Administered By Caremark, Trailblazer Health

Executive Summary

Caremark/AdvancePCS and Trailblazer Health Enterprises will administer the Medicare Part B replacement drug demonstration project

You may also be interested in...



Medicare Oral Drug Demonstration A Dud; Will Part D Enrollment Take Off?

Enrollment challenges with the Medicare oral drug replacement demonstration project are highlighting possible stumbling blocks in the Part D implementation process

Medicare Oral Drug Demonstration A Dud; Will Part D Enrollment Take Off?

Enrollment challenges with the Medicare oral drug replacement demonstration project are highlighting possible stumbling blocks in the Part D implementation process

Marketing Part D As Insurance Is Key To Success, PacifiCare Exec Says

Medicare Part D plan sponsors that can persuade seniors to view the drug benefit as insurance will be the most sucessful, PacifiCare Corporate VP-Public Policy Janet Newport said

Related Content

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel